Clarus Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
15 sept. 2021 09h05 HE
|
Clarus Therapeutics Holdings, Inc.
NORTHBROOK, Ill., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Nasdaq:CRXT), a specialty pharmaceutical company dedicated to providing solutions to unmet medical needs by...
Clarus Therapeutics Announces Comprehensive Settlement of Patent Litigation With Lipocine
15 juil. 2021 09h00 HE
|
Clarus Therapeutics, Inc.
NORTHBROOK, Ill., July 15, 2021 (GLOBE NEWSWIRE) -- Clarus and Lipocine (NASDAQ: LPCN) agreed to settle all outstanding claims in the patent infringement lawsuit brought against Clarus by Lipocine...
Everwell Announces the Launch of Health and Wellness Clinic That Merges Conventional and Alternative Therapies
30 mars 2021 13h30 HE
|
Everwell Medical Management, Inc.
NEWPORT BEACH, Calif., March 30, 2021 (GLOBE NEWSWIRE) -- Everwell announces the launch of the Everwell health and wellness clinic, open now in Newport Beach, California. Everwell provides a select...
Steroids for sale - the dangers TRT patients are facing to avoid high cost prescriptions
25 mars 2021 13h00 HE
|
Secrets Of Bodybuilding
LOS ANGELES, March 25, 2021 (GLOBE NEWSWIRE) -- Secrets Of Bodybuilding - TRT (Testosterone Replacement Therapy) has massively grown in popularity over the last six years giving many patients back...
Marius Pharmaceuticals Receives PDUFA Date for KYZATREX® NDA for Treatment of Hypogonadism
11 mars 2021 10h00 HE
|
Marius Pharmaceuticals LLC
RALEIGH, N.C., March 11, 2021 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) goal...
Marius Pharmaceuticals Announces Co-CEOs Himanshu H. Shah and Shalin Shah to Drive Growth ahead of Anticipated FDA Action of its Lead Asset, KYZATREX
28 janv. 2021 10h00 HE
|
Marius Pharmaceuticals LLC
RALEIGH, N.C., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a specialty pharmaceutical company focusing on treating conditions that are primarily associated with testosterone...
Clarus Announces JATENZO® (Testosterone Undecanoate) Capsules, CIII Now Covered by Express Scripts
07 déc. 2020 09h00 HE
|
Clarus Therapeutics, Inc.
JATENZO is the first and only FDA-approved oral testosterone replacement therapy of its kind Coverage effective December 1, 2020 on the Express Scripts National Preferred, Basic and High Performance...
Marius Pharmaceuticals Announces Issuance of Two Key Patents Protecting its Proprietary Oral Testosterone Therapy
21 mai 2020 06h30 HE
|
Shah Capital
RALEIGH, N.C., May 21, 2020 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals announced today that the United States Patent and Trademark Office (USPTO) has issued two key patents related to its lead...
CLARUS THERAPEUTICS ANNOUNCES FINANCING TO SUPPORT THE COMMERCIAL LAUNCH AND AVAILABILITY OF JATENZO® (TESTOSTERONE UNDECANOATE) CAPSULES, CIII FOR THE TREATMENT OF HYPOGONADISM
16 mars 2020 08h00 HE
|
Clarus Therapeutics, Inc.
Financing to speed commercialization of the only FDA-approved oral treatment of its kind for testosterone deficiency1,2 NORTHBROOK, Ill., March 16, 2020 (GLOBE NEWSWIRE) -- Clarus Therapeutics,...
Clarus Therapeutics Announces Commercial Launch and Availability of JATENZO® (testosterone undecanoate) capsules, CIII for the Treatment of Hypogonadism
10 févr. 2020 08h00 HE
|
Clarus Therapeutics, Inc.
First and only FDA-approved oral treatment of its kind for testosterone deficiency1,2 NORTHBROOK, Ill., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Clarus Therapeutics, Inc. today announced that JATENZO®...